Combined Treatment of RFA and Sorafenib on Recurrent HCC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

430 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RFA is a routaine treatment of recurrent HCC. Recently Sorafenib was reported to be a promising drug to treat late stage HCC. But few studies were related with its effectiveness on recurrent HCC. So the investigators hypothesized that combined RFA and Sorafenib might reduce the frequency of recurrence and improve the overall survival and disease free survial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC

NCT02187081

HCC

UNKNOWN NA

Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma

NCT03097848

HCC

UNKNOWN NA

Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) Therapy

NCT04707547

Liver Cancer

COMPLETED PHASE4

Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma

NCT05444478

Hepatocellular Carcinoma Microwave Ablation Liver Cancer +2 more

RECRUITING NA

RFA Versus SBRT for Recurrent Small HCC

NCT04047173

Hepatocellular Carcinoma

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HCC Radiofrequency Ablation Sorafenib

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RFA+Sorafenib

to treat recurrent HCC both with RFA and Sorafenib

Group Type EXPERIMENTAL

RFA + Sorafenib

Intervention Type OTHER

combined RFA and Sorafenib to treat recurrent HCC

RFA group

To treat recurrent HCC with RFA

Group Type ACTIVE_COMPARATOR

RFA

Intervention Type OTHER

treat Recurrent HCC with RFA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RFA + Sorafenib

combined RFA and Sorafenib to treat recurrent HCC

Intervention Type OTHER

RFA

treat Recurrent HCC with RFA

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* recurrent HCC after curative resection
* without gender restriction
* age between 18 to 75 years
* The liver function showed no worse than Child-Pugh B
* tumor nodes were less than 5cm and no more than 3 nodules

Exclusion Criteria

* Pregnancy patients
* With extrahepatic tumor or lymphnode metastasis
* Tumor invasion or thrombosis in portal vein,hepatic vein or inferior vena cava

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No